Literature DB >> 399858

Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients.

J P Hartley, S G Nogrady, A Seaton.   

Abstract

Salbutamol dry powder was compared with salbutamol aerosol in 38 asthmatic patients. The study was double-blind and took place over six months. Salbutamol powder in a dose of 200 micrograms per capsule was able to control asthma as well as the aerosol, but some patients needed to increase the frequency of dosage when using the powder. The device used for powder administration, the Rotahaler, was well accepted and was preferred to the pressurized aerosol by one-third of patients. Dry powder administered by Rotahaler allows salbutamol to be given by inhalation to many patients previously using aerosols inefficiently.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 399858

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  5 in total

Review 1.  Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD).

Authors:  J Wright; D Brocklebank; F Ram
Journal:  Qual Saf Health Care       Date:  2002-12

2.  Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.

Authors:  F S Ram; J Wright; D Brocklebank; J E White
Journal:  BMJ       Date:  2001-10-20

3.  Comparison of inhaled salbutamol powder and aerosol in asthmatic patients with low peak expiratory flow level.

Authors:  H Tukiainen; E O Terho
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.

Authors:  B M Zainudin; M Biddiscombe; S E Tolfree; M Short; S G Spiro
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

Review 5.  Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.

Authors:  D A Hughes; A Woodcock; T Walley
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.